Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line

References

• SilmanAJHochbergMCEpidemiology of the rheumatic diseasesNew York, USAOxford University Press2001
   Google Scholar
• HuscherDMerkesdalSThieleKZeidlerHSchneiderMZinkAGerman Collaborative Arthritis CentresCost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in GermanyAnn Rheum Dis20066591175118316540552
   PubMed Web of Science ®Google Scholar
• SalaffiFCarottiMGaspariniSIntorciaMGrassiWThe health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy peopleHealth Qual Life Outcomes200972519296831
   PubMed Web of Science ®Google Scholar
• Stevens SethRChang TingHHistory of development of TNF inhibitorsBasel, SwitzerlandSpringer2006922
   Google Scholar
• Navarro CoyNCBrownSBosworthAThe ‘Switch’ study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drugBMC Musculoskelet Disord20141545225539805
   PubMed Web of Science ®Google Scholar
• CohenSBEmeryPGreenwaldMWRituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeksArthritis Rheum20065492793280616947627
   PubMed Web of Science ®Google Scholar
• EmeryPKeystoneETonyHPIL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trialAnn Rheum Dis200867111516152318625622
   PubMed Web of Science ®Google Scholar
• GenoveseMCBeckerJ-CSchiffMAbatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibitionN Engl J Med2005353111114112316162882
   PubMed Web of Science ®Google Scholar
• SmolenJSKayJDoyleMKGolimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trialLancet2009374968521022119560810
   PubMed Web of Science ®Google Scholar
• WeinblattMEFleischmannRHuizingaTWEfficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb studyRheumatology201251122204221422923753
   PubMed Web of Science ®Google Scholar
• BraunJvan den BergRBaraliakosX2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitisAnn Rheum Dis201170689690421540199
   PubMed Web of Science ®Google Scholar
• SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateAnn Rheum Dis20130118
   Google Scholar
• GossecLSmolenJSRamiroSEuropean League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 updateAnn Rheum Dis201510.1136/annrheumdis-2015-208337
   Web of Science ®Google Scholar
• AletahaDSmolenJSEffectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational studyJ Rheumatol20022981631163812180721
   PubMed Web of Science ®Google Scholar
• FriesJFEffectiveness and toxicity considerations in outcome directed therapy in rheumatoid arthritisJ Rheumatol Suppl1996441021068833065
   PubMedGoogle Scholar
• PincusTMarcumSBCallahanLFLongterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisoneJ Rheumatol19921912188518941294735
   PubMed Web of Science ®Google Scholar
• ChatzidionysiouKKristensenLEErikssonJAsklingJvan VollenhovenRGroup ArtisEffectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish registerScand J Rheumatol201544643143726084325
   PubMed Web of Science ®Google Scholar
• FagerliKMLieEvan der HeijdeDSwitching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD studyAnn Rheum Dis2013721840184423562987
   PubMed Web of Science ®Google Scholar
• GlintborgBØstergaardMKroghNSClinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO RegistryArthritis Rheum20136551213122323460467
   PubMed Web of Science ®Google Scholar
• GlintborgBØstergaardMKroghNSTClinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registryAnn Rheum Dis20137271149115522941767
   PubMed Web of Science ®Google Scholar
• Gomez-ReinoJJCarmonaLGroup BIOBADASERSwitching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year periodArthritis Res Ther20068117
   Web of Science ®Google Scholar
• GulyasKBodnarNNagyZReal-life experience with switching TNF-α inhibitors in ankylosing spondylitisEur J Health Econ20141519310023436142
   PubMed Web of Science ®Google Scholar
• HyrichKLLuntMWatsonKDSymmonsDPSilmanAJOutcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a large UK national cohort studyArthritis Rheum2007561132017195186
   PubMed Web of Science ®Google Scholar
• LieEvan der HeijdeDUhligTEffectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD registerAnn Rheum Dis201170115716321062852
   PubMed Web of Science ®Google Scholar
• Rosales-AlexanderJLAznarJBPérez-VicenteSMagro-ChecaCDrug survival of anti-tumour necrosis factor α therapy in spondyloarthropathies: results from the Spanish emAR II StudyRheumatology2015
   Web of Science ®Google Scholar
• SaevarsdottirSSantacatterinaMTuressonCForsbladHJacobssonLLindbladSClinical characteristics and outcome of golimumab treatment differs between bio-naive and patients previously exposed to biologicals. Nationwide results on rheumatoid arthritis (RA), psoriatic arthritis (PSA), ankylosing spondylitis (AS) and other spondyloarthritides (SPA)Arthritis Rheum201466S705
   Google Scholar
• Pharmaceuticals – statistics for 2014The National Board of Health and Welfare (Socialstyrelsen) Available from: https://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/19768/2015-3-17.pdfAccessed August 20, 2015
   Google Scholar
• LudvigssonJFAnderssonEEkbomAExternal review and validation of the Swedish national inpatient registerBMC Public Health20111145021658213
   PubMed Web of Science ®Google Scholar
• The National Board of Health and Welfare (Socialstyrelsen)Causes of Death2013 Available from: https://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/19736/2015-2-42.pdfAccessed August 20, 2015
   Google Scholar
• CramerJARoyABurrellAMedication compliance and persistence: terminology and definitionsValue Health2008111444718237359
   PubMed Web of Science ®Google Scholar
• RosenbaumPRRubinDBConstructing a control group using multivariate matched sampling methods that incorporate the propensity scoreAmerican Statistician19853913338
   Web of Science ®Google Scholar
• AustinPCBalance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samplesStatistics Med2009282530833107
   PubMed Web of Science ®Google Scholar
• HoDEImaiKKingGStuartEAMatching as nonparametric preprocessing for reducing model dependence in parametric causal inferencePolit Anal2007153199236
   Web of Science ®Google Scholar
• ImaiKKingGStuartEAMisunderstandings between experimentalists and observationalists about causal inferenceJ R Stat Soc Ser A Stat Soc20081712481502
   Web of Science ®Google Scholar
• DeodharAStrandVKayJBraunJThe term ‘non-radiographic axial spondyloarthritis’ is much more important to classify than to diagnose patients with axial spondyloarthritisAnn Rheum Dis201675579179426768406
   PubMed Web of Science ®Google Scholar
• MeissnerBTrivediDYouMRosenblattLSwitching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world settingJ Med Econ201417425926524575891
   PubMedGoogle Scholar
• DalénJSvedbomABlackCMTreatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistenceRheumatol Int20161926194148
   PubMed Web of Science ®Google Scholar
• KonczTPentekMBrodszkyVErsekKOrlewskaEGulacsiLAdherence to biologic DMARD therapies in rheumatoid arthritisExpert Opin Biol Ther20101091367137820681888
   PubMed Web of Science ®Google Scholar
• OsterbergLBlaschkeTAdherence to medicationN Engl J Med2005353548749716079372
   PubMed Web of Science ®Google Scholar
• NeoviusMSundstromASimardJSmall-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009Scand J Rheumatol201140181520955087
   PubMed Web of Science ®Google Scholar